Hostname: page-component-586b7cd67f-t7czq Total loading time: 0 Render date: 2024-11-26T20:06:04.821Z Has data issue: false hasContentIssue false

420 A novel mouse model of COVID-19

Published online by Cambridge University Press:  24 April 2023

Branka Milicic Stanic
Affiliation:
Department of Medicine, Georgetown University, Washington, DC
Nisha Dugal
Affiliation:
Department of Biomedical Sciences and Pathobiology, Virginia Tech, Blacksburg, VA
Nataliia Shults
Affiliation:
Department of Pharmacology & Physiology, Georgetown University, Washington, DC
Hong Ji
Affiliation:
Department of Medicine, Georgetown University, Washington, DC
Aline M.A. de Souza
Affiliation:
Department of Medicine, Georgetown University, Washington, DC
Seth Hawkins
Affiliation:
Department of Biomedical Sciences and Pathobiology, Virginia Tech, Blacksburg, VA
Xie Wu
Affiliation:
Department of Medicine, Georgetown University, Washington, DC
Juan M. Saavedra
Affiliation:
Department of Pharmacology & Physiology, Georgetown University, Washington, DC
Kathryn Sandberg
Affiliation:
Department of Medicine, Georgetown University, Washington, DC
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

OBJECTIVES/GOALS: Rodents are the most widely used experimental animals to study disease mechanisms due to their availability and cost-effectiveness. An international drive to investigate the pathophysiology of COVID-19 is inhibited by the resistance of rats and mice to SARS-CoV-2 infection. Our goal was to establish an appropriate small animal model. METHODS/STUDY POPULATION: To recreate the cytokine storm that is associated with COVID-19, we injected angiotensin converting enzyme 2 knockout (ACE2KO) mice (C57BI/6 strain) with lipopolysaccharide (LPS) intraperitoneally and measured the expression of multiple cytokines as a function of time and LPS dose. We then chose a minimum dose (500ug/kg) and time (3h) when multiple cytokines were elevated to measure lung injury scores using a point-counting technique on tissue sections stained with hematoxylin and eosin. The data are expressed as mean percentage of grid points lying within the peribronchial and superficial area in up to 20 fields. Percentage of peribronchial and superficial intrapulmonary hemorrhage, congestion, neutrophil infiltration and area of alveolar space were all assessed. RESULTS/ANTICIPATED RESULTS: Compared to the wildtype group (WT-G), the LPS-injected ACE2KO mice (LPS-G) exhibited a higher percentage of peribronchial intrapulmonary hemorrhage [(%): LPS-G, 10.56 ± 2.06 vs. WT-G, 5.59 ± 0.53; p DISCUSSION/SIGNIFICANCE: Establishing this novel mouse model of COVID-19 will facilitate studies investigating tissue-specific mechanisms of pathogenesis in this disease. This model can also be used to discover novel therapeutic targets and the design of clinical trials focusing on diagnostics, treatments and outcomes in COVID-19.

Type
Team Science
Creative Commons
Creative Common License - CCCreative Common License - BYCreative Common License - NCCreative Common License - ND
This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.
Copyright
© The Author(s), 2023. The Association for Clinical and Translational Science